InvestorsHub Logo
Followers 5
Posts 280
Boards Moderated 0
Alias Born 08/29/2015

Re: BIOChecker4 post# 153991

Monday, 06/25/2018 1:22:35 PM

Monday, June 25, 2018 1:22:35 PM

Post# of 459491
Thank you for the link. Looking over the presentation it shows a lack of sophistication on how quickly their drug candidates would proceed.
As We approach up coming trials, I believe the new management is more realistic in their timeline estimations having been burned once already. I remain steadfast in the science and ultimate large size of market that 2-73 will control.
The presentation also gave estimated revenue numbers for all of the drugs in the pipeline; looks like they didn't do a good job determining how much money 2-73 has potiential to create. They probably didn't have a good idea of the scope due to research that was being or yet to be conducted.
So yes the company has over promised before, luckily we have new management that appears to have a much better grasp on what is needed to bring our drug to the finishline.
I think they also have a much better idea of potiential revenue, using estimates from UBS and Biogen on how large the CNS revenue will become.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News